drugset / Trial / NCT05796167
Pimavanserin for Sleep in Parkinson Disease
Phase 0
Withdrawn
State University of New York - Downstate Medical Center
ACADIA Pharmaceuticals Inc. · collab
NaSingle-groupOpen-labelOther
Summary
This pilot, self-control study is for patients with Parkinson's Disease (PD) psychosis (e.g., visual hallucinations, delusions) and sleep problems.
Timeline
- Start
- 2023-01-27
- Primary completion
- 2024-06-24
- Completion
- 2024-06-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pimavanserin | Small molecule | 34 mg | Oral |